Welcome to our dedicated page for Evolus news (Ticker: EOLS), a resource for investors and traders seeking the latest updates and insights on Evolus stock.
Evolus, Inc. (NASDAQ: EOLS) is a performance beauty company focused on aesthetic injectables, and its news flow reflects both commercial execution and product development in this space. Company press releases highlight its mission to build an aesthetic portfolio anchored by Jeuveau, a neurotoxin dedicated exclusively to aesthetics, and Evolysse, a collection of injectable hyaluronic acid (HA) gels. Readers following EOLS news can see how these product families shape the company’s growth in the self-pay aesthetic market.
News updates frequently cover financial results and guidance, including quarterly net revenue, product mix between global Jeuveau revenue and Evolysse revenue, and commentary on non-GAAP operating income. Management discussions in these releases describe trends in customer accounts, reorder rates, and loyalty program participation through the Evolus Rewards consumer program, providing insight into adoption of the company’s injectables.
Evolus news also features clinical and regulatory milestones for its HA filler portfolio. For example, the company has reported positive topline data from a pivotal study of Evolysse Sculpt, an injectable HA gel product designed to restore mid-face volume, and described the submission of a Premarket Approval application to the U.S. Food and Drug Administration. Additional updates discuss the U.S. commercialization of Evolysse Form and Evolysse Smooth and anticipated timelines for Evolysse Sculpt and Estyme-branded products in Europe.
Investors and industry observers can also find corporate and governance updates in Evolus news, such as executive appointments, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and participation in healthcare and investor conferences. Together, these items provide a view of how Evolus manages its leadership, capital incentives, and investor outreach as it pursues its performance beauty strategy. Bookmarking the EOLS news page allows users to monitor ongoing developments in financial performance, product launches, clinical data, and corporate actions related to Evolus’ aesthetic injectable business.
Evolus has announced positive topline results from a U.S. pivotal study for its dermal fillers, Evolysse™ Lift and Smooth. Presented at the 2024 SCALE Meeting, the study showed that both products met primary and secondary endpoints, demonstrating superiority over Restylane-L in improving nasolabial fold severity at multiple time points. The safety profiles of the products were similar to Restylane-L with no serious adverse events. Evolus plans to submit Premarket Approval applications to the FDA within the next 90 days, potentially expanding their market by 78%, complementing their neurotoxin Jeuveau®.
Evolus celebrates the fifth anniversary of its flagship product, Jeuveau®, at the Women's Wear Daily (WWD) Beauty CEO Summit, where CEO David Moatazedi speaks.
Jeuveau® has been the fastest-growing aesthetic neurotoxin in the U.S. over the last three years, emphasizing the company's market impact. Evolus aims to redefine beauty through its performance beauty approach, focusing on younger demographics. The summit highlights Evolus' role in driving growth and innovation in global beauty.
Moatazedi reflects on Evolus' progress, evolving from a single-product company to a multi-product innovator in the beauty aesthetics space.
Evolus, Inc. reported granting stock options and restricted stock units to 14 new non-executive employees under the 2023 Inducement Incentive Plan. The awards have a vesting commencement date of May 7, 2024, with stock options priced at $13.42 per share and a 10-year term. RSUs vest annually over 4 years. The grants are compliant with Nasdaq Listing Rule 5635(c)(4).
Evolus, Inc. announced that Sandra Beaver, the Chief Financial Officer, has been honored as the Public Company CFO of the Year by the Orange County Business Journal. Since joining in 2022, she has significantly contributed to the company's growth and success. Sandra supported the licensing agreements expanding the product portfolio by adding late-stage dermal fillers in the U.S. and European markets, increasing the addressable market by 78% to $6 billion. She also led the geographic expansion to Austria, Germany, and Italy, guiding the company to financial success and strategic decision-making.
Evolus, Inc. (NASDAQ: EOLS) reported Q1 2024 net revenue of $59.3 million, a 42% increase from Q1 2023. They aim for non-GAAP profitability in Q4 2024 and full year 2025. The company completed U.S. clinical trials for Evolysse® Lift and Smooth fillers, with FDA submission expected soon. Evolus reaffirmed full-year 2024 net revenue guidance of $255 million to $265 million, on track to achieve total net revenue goal of $700 million by 2028.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.